news aktuell GmbH

Late-breaking data from the Phase III RISE trial further strengthen the well-established efficacy and safety profile of Qutenza®. Post-surgical neuropathic pain is a debilitating complication of surgery affecting millions of patients every year.¹ Aachen, Germany, 28 October 2026 – Grünenthal, a global leader in pain management and research, today announced new data from the Phase III RISE trial (NCT04967664), evaluating Qutenza® versus control in people with post-surgical neuropathic pain. These data were shared today as late-breaking poster presentations at the 2026 International Association for the Study of Pain (IASP) World Congress on Pain in Bangkok, Thailand. The trial (n=409) showed that Qutenza® achieved a statistically significantly greater reduction in average pain intensity (API) than the control treatment over weeks 2-12, meeting one of its pre-specified primary endpoints. When evaluating API at week 12 specifically, at the point when patients would typically return for ret

Why should the camping season end just because summer is over? The colder months offer unique experiences—from skiing and snowshoeing to simply enjoying the winter landscape. To ensure your motorhome or campervan remains a comfortable retreat even in low temperatures, the right heating solution is crucial.

With Polarise Rise and Polarise Drive, the German AI provider extends its own European AI Factories into a full-stack sovereign cloud

New York/DNA - A newly released study of US state government performance found strong partisan and regional patterns within three pillars of governance: democratic accountability, state capacity and public goods provision. Yet, the US states’ outcomes differ in important ways from international comparisons, as the three governance dimensions show limited correlation, the researchers found. The report, “The Governance Performance of the Fifty States: The U.S. Berggruen Governance Index”, applies the research team’s “governance triangle” from past global country rankings to the 50 US states. The report has now been presented to the public at Columbia University in New York. “Unlike in the Berggruen Governance Index’s cross-national comparisons, where the three dimensions are broadly correlated, in the 50 U.S. states they often run counter to each other,” the authors conclude. “This may seem counterintuitive, as one might expect a well-governed state to finish high on all three and a poor

New managed service provides transparency into the AI landscape and helps companies centrally manage AI, monitor risks and regulatory requirements, and highlight business benefits.

Potential first-in-class, selective nociceptin receptor (NOP) agonist that aims to provide safe, effective treatment for moderate to severe acute pain. Following successful Phase I results earlier this year demonstrating an excellent safety profile, the program has now progressed to Phase II. The randomized, double-blind, double-dummy, placebo- and active controlled, 2-part Phase II trial will evaluate the safety, tolerability and efficacy of this novel NOP agonist in patients post bunionectomy surgery. Grünenthal anticipates reporting results in early 2028.

Los Angeles/DNA - For the first time since the Hamas attacks of three years ago, Israel is set to go to the polls on October 27 to elect the members of the 26th Knesset. In 2023 the country was in the top group of ‘consolidated democratic states’, according to the 2026 Berggruen Governance Index (BGI), just as it had been in 2000. However, according to a new report from governance experts, the wars unleashed on multiple fronts in rapid succession following the Hamas attacks launched from Gaza have changed Israel politically, economically, and socially. The report ‘Israeli Governance Performance: The 2026 Elections, Democracy and Future Scenarios’ was produced by researchers at the University of California, Los Angeles (UCLA), the Los Angeles-based Berggruen Institute, and Berlin’s Hertie School. The ongoing election campaign, which never stopped despite the longest war in Israel’s history, is about to conclude with voting at the ballot box, in what the entire population is experiencing

Brussels – The Socialists and Democrats (S&D) Group in the European Parliament is stepping up political pressure for an ambitious European framework for quality jobs. At the “Quality Jobs for All” conference in Brussels on 14 October, the impact of artificial intelligence, digital surveillance, precarious employment conditions and growing work-related stress was at the centre of the debate. The conference took place as the European Commission is expected to present its proposal for a Quality Jobs Act in December 2026. Quality Jobs for All is one of the S&D Group’s six flagship political priorities, set out under their Strategic Turn initiative in recent months. Jobs and the labour markets are changing rapidly, with automation and artificial intelligence able to fundamentally change professions and their inherent activities. At the same time, concerns are growing about job cuts, wage pressure, social exclusion and the loss of workers’ voices at work. Experts at the conference have warne

Berlin, October 14, 2026 - The World Health Summit 2026 concluded with new funding commitments, research findings, and initiatives. Under the theme “From Crisis to Resilience: Innovating for Health,” the Summit convened more than 4,000 on-site participants from 130 countries and territories, generated over 50,000 livestream views, and featured more than 400 speakers, including 20 ministers and state secretaries, across 76 sessions.

Nuremberg – Innomotics, a globally leading provider of electric motors and large drive systems, has earned the coveted EcoVadis Silver Medal in its first-ever assessment. With a strong score of 74 out of 100 points, the company now ranks among the global top 15% of more than 150,000 rated companies. First EcoVadis Rating as Innomotics Participation in the EcoVadis assessment marks an important milestone in Innomotics’ sustainability journey. As a relatively young, independent organization, the first rating provided the opportunity to benchmark its sustainability management against an internationally recognized framework and demonstrate the progress made since becoming a standalone company. Silver Medal: Top 15% Globally The EcoVadis Silver Medal is awarded to the top 15% of companies assessed worldwide. With its achieved score of 74 points, Innomotics not only confirms its position within this leading group but also demonstrates that it meets the rating’s rising requirements – the thre

Berlin, October 11, 2026 The World Health Summit (WHS) 2026, the leading platform for global health, brings together more than 4,000 participants from 130 countries in Berlin and tens of thousands more online from October 11 to 13. Under the theme "From Crisis to Resilience: Innovating for Health," the Summit convenes leaders from politics, science, civil society, and the private sector. Discussions address Ebola and other infectious diseases, antibiotic resistance, pandemic preparedness, resilient health systems, health care in conflict settings such as Ukraine, and climate-related health threats. The Summit will also address WHO leadership through a conversation with prospective candidates for the next WHO Director-General. Against this backdrop, WHS President Axel R. Pries emphasized the need for innovation and collaboration: "Past achievements and continued progress in global health are increasingly challenged by multiple and overlapping crises. To build resilient, effective, and e

DRF Luftrettung and DRF Maintenance are joining forces: the newly established DRF Aviation Services combines the two companies’ technical expertise built on more than 50 years of experience in helicopter maintenance, modifications and services. As a “one-stop shop”, DRF Aviation Services provides the full range of services from a single source. Helicopter operators benefit from high levels of reliability and innovative capability.

Ruggell (LI), 1 October 2026 – RM Equity Partners (RMEP), the international investment firm focused on asset-light digital businesses, today announces the completion of its generational handover. As of 1 October 2026, the management company is fully owned by the three partners Eugen Benedikt Russ, Chris Wittlinger and Nicola Szekely and the wider team, who will make all new investments independently. With this step, the succession within the founding family is concluded: RMEP operates as a fully independent investment firm with no ownership, management or personnel ties to the Russmedia group. RMEP has grown into one of the most active investors in digital marketplaces, software and consumer platforms in Europe: Assets under management of more than €500 million Annual investment capacity of more than €100 million 50+ portfolio investments, with 95% of revenue generated outside Austria Independent evergreen structure – the partners invest their own capital (principal investing, no exter

7,000 Humanoids emerge as new market 117,000 Transport and logistics’ robots lead as top application

Berlin / Germany, 30 September 2026 – ABDA – Federal Union of German Associations of Pharmacists has published its Statistical Yearbook “German Pharmacies: Figures, Data, Facts 2026”. The 132-page publication provides a comprehensive overview of the most important facts and statistics of the pharmacy market as well as information on the latest trends in the pharmaceutical and healthcare sectors in Germany and beyond.

World's first and only commercially available cochlear implant with all components implanted beneath the skin Continuous hearing day and night Hearing performance designed to be the same as established cochlear implant solutions September 29, 2026 – (Innsbruck, Austria): MED-EL, a global leader in hearing implant technology, today announced the launch of TICI UNICO, the world's first and only commercially available totally invisible cochlear implant. Designed for people with severe-to-profound hearing loss, TICI UNICO enables continuous hearing 24 hours a day while remaining completely beneath the skin. It has received CE Mark approval and is being introduced in European markets.

The partnership will bring Qutenza®, Vimovo®, Palexia® and Zomig® to people living with pain in Asia-Pacific, spanning Hong Kong, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand and Vietnam. Pain is a significant healthcare challenge in the region, due to the ageing population and the high burden of chronic diseases.[i],[123], The partnership is a key step in Grünenthal’s strategy to enhance patient care and expand access to its innovative medicines.

From Albania to Uzbekistan – visitors from almost 90 nations Trade visitors from 89 nations to date, international delegations and companies from more than 40 countries: Security Essen and the new Euro Defence Expo (EUDEX) are bringing guests from numerous parts of the world to Messe Essen this week. Visitors from the Netherlands, Belgium, Switzerland, the UK, Poland, the Czech Republic and France are particularly well represented. But experts are also travelling from more distant countries such as Argentina, Ukraine, Singapore and South Korea to network across borders and find out about the latest security and defence technologies. Security Essen focuses on civil security, whilst the inaugural EUDEX is dedicated to the defence industry.

Thermomix® takes its ecosystem to the next level: With the new Cookidoo® Assistant and Recipe Translation benefits, the largest culinary community gains comprehensive AI features. In addition, Arabic is introduced as a new language option on Thermomix® TM7, following a long-standing community demand.

Latest step in Grünenthal’s strategy to acquire established medicines that serve clear medical needs, leverage its commercial and operational capabilities, and drive growth. Stivarga® (regorafenib) is an established oral treatment for certain advanced cancers, including metastatic colorectal cancer, gastrointestinal stromal tumours (GIST) and hepatocellular carcinoma (liver cancer). It is approved and available in more than 90 markets worldwide. Grünenthal has invested around €2.6 billion in successful M&A transactions since 2017, significantly strengthening its profitability and further funding its innovative research pipeline.